Skip to content

other

Emicizumab (Hemlibra)

A bispecific antibody for hemophilia A that binds clotting factors IX and X so they can react as they would with the missing factor VIII. First approved by the FDA in 2017.

Known aliases

  • Hemlibra

Relationships

No evidence-backed relationships are recorded.

Current clusters